ArticleJPGN reports2026
Endoscopic findings in patients with Shwachman-Diamond syndrome: A report from the North American Shwachman-Diamond syndrome registry.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Objectives: Shwachman-Diamond syndrome (SDS) is an inherited bone marrow failure disorder, and its endoscopic phenotype is poorly defined. We sought to characterize endoscopic findings in patients with genetically confirmed SDS. Methods: Retrospective registry study of 45 patients with biallelic Shwachman-Bodian-Diamond syndrome mutations and evaluable endoscopic procedures. Clinical, laboratory, imaging, endoscopic reports, and biopsy findings were extracted from patient medical records. Results: Among 45 patients with genetically confirmed SDS, 102 endoscopic procedures were performed, most commonly esophagogastroduodenoscopy (EGD, 58.8%). The leading indication was diarrhea and/or steatorrhea (23.6%). Abnormal biopsy findings were most frequent in patients with dysphagia/dyspepsia or gastrointestinal bleeding and were strongly associated with elevated C-reactive protein and abnormal hepatic enzymes. Most pre-procedural imaging studies were normal (63.4%). Pre-hematopoietic stem cell transplant (HSCT) biopsies were largely normal, with occasional mild acute or chronic inflammation in the esophagus, stomach, and duodenum. In contrast, post-HSCT biopsies showed more diverse abnormalities, including inflammation, basal crypt apoptosis, and graft-versus-host disease (GVHD)-associated changes. Central pathology review also identified rare findings such as adenoviral infection and mild or equivocal GVHD in post-transplant samples. Conclusions: Endoscopic evaluation in patients with SDS demonstrates heterogeneous histopathologic findings, with diagnostic yield influenced by clinical indication, laboratory abnormalities, and transplant status. Routine endoscopy in asymptomatic or nonspecifically symptomatic patients may have limited value, whereas targeted evaluation based on symptoms or supportive laboratory findings may improve diagnostic yield. These findings provide updated insight into gastrointestinal manifestations of SDS and may help guide clinical decision-making regarding endoscopic evaluation in this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.